Terms: = Prostate cancer AND HOXA11, HOX1, 3207, ENSG00000005073, HOX1I, P31270 AND Treatment
4 results:
1. Targeting hoxa11-AS to mitigate prostate cancer via the glycolytic metabolism: In vitro and in vivo.
Zhang J; Li S; Zhang M; Wang Z; Xing Z
J Cell Mol Med; 2024 Apr; 28(8):e18227. PubMed ID: 38520207
[TBL] [Abstract] [Full Text] [Related]
2. Interventions for Improving Body Composition in Men with prostate cancer: A Systematic Review and Network Meta-analysis.
Lopez P; Newton RU; Taaffe DR; Singh F; Lyons-Wall P; Buffart LM; Tang C; Hayne D; Galvão DA
Med Sci Sports Exerc; 2022 May; 54(5):728-740. PubMed ID: 34935706
[TBL] [Abstract] [Full Text] [Related]
3. CTCF-induced upregulation of hoxa11-AS facilitates cell proliferation and migration by targeting miR-518b/ACTN4 axis in prostate cancer.
Xing Z; Li S; Liu Z; Zhang C; Bai Z
Prostate; 2020 Apr; 80(5):388-398. PubMed ID: 31971633
[TBL] [Abstract] [Full Text] [Related]
4. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract] [Full Text] [Related]
